RDInvesting Provides Investors with Free In-Depth Equity Reports on AXAS, BLUE, ONXX and TROV


Follow this company

Companies Mentioned

NASDAQ:AXAS / NASDAQ:BLUE / NASDAQ:ONXX / NASDAQ:TROV
07/16/2013 [ACCESSWIRE]

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Abraxas Petroleum Corp. (NASDAQ: AXAS) shares spiked 3.0 percent to close at $2.40 a share Monday. The stock traded between $2.33 and $2.40 on volume of 562,516 shares traded. Analysts at Sidoti have recently upgraded the company’s rating to “buy” from “neutral”. Shares of Abraxas Petroleum have gained approximately 9.5 percent year-to-date.

Find out more about Abraxas Petroleum including full access to the free equity report at:       
www.RDInvesting.com/AXAS

Bluebird Bio Inc. (NASDAQ: BLUE) shares jumped 6.04 percent to close at $32.50 a share Monday. The stock traded between $32.01 and $33.20 on volume of 333,237 shares traded. Analysts at JPMorgan have recently initiated coverage on the company with an “overweight” rating and a price target of $44.00. Shares of Bluebird Bio have fallen approximately 13.2 percent year-to-date.

Find out more about Bluebird Bio including full access to the free equity report at:       
www.RDInvesting.com/BLUE

Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) shares declined 1.38 percent to close at $131.17 a share Monday. The stock traded between $130.93 and $132.90 on volume of 2.09 million shares traded. Analysts at JMP Securities have recently downgraded the company’s rating to “market perform” from “outperform”. Shares of Onyx Pharmaceuticals have gained approximately 73.7 percent year-to-date.

Find out more about Onyx Pharmaceuticals including full access to the free equity report at:    
www.RDInvesting.com/ONXX

TrovaGene Inc. (NASDAQ: TROV) shares declined 2.69 percent to close at $6.87 a share Monday. The stock traded between $6.85 and $7.36 on volume of 264,411 shares traded. Analysts at Cantor have recently initiated coverage on the company with a “buy” rating and a price target of $10.00.

Find out more about TrovaGene including full access to the free equity report at:       
www.RDInvesting.com/TROV

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing 
info@rdinvesting.com

COMMENTS

Leave a comment...
 * 

Your Name
 *